Fate Therapeutics, Inc. (FATE) Analysts See $-0.26 EPS

February 15, 2018 - By Clifton Ray

 Fate Therapeutics, Inc. (FATE) Analysts See $ 0.26 EPS
Investors sentiment increased to 1.79 in 2017 Q3. Its up 0.36, from 1.43 in 2017Q2. It is positive, as 3 investors sold Fate Therapeutics, Inc. shares while 16 reduced holdings. 17 funds opened positions while 17 raised stakes. 24.55 million shares or 4.67% less from 25.76 million shares in 2017Q2 were reported.
Vanguard Group reported 1.28M shares stake. 21,533 were accumulated by Voya. Tiaa Cref Invest Mngmt Llc has 102,021 shares. Guggenheim Capital Ltd Liability Corporation invested 0% in Fate Therapeutics, Inc. (NASDAQ:FATE). Creative Planning reported 28,000 shares. Geode Cap Management Ltd Com has 302,431 shares. Legal & General Public Limited Com holds 0% or 5,627 shares in its portfolio. Sg Americas Securities Limited Liability Com owns 10,596 shares for 0% of their portfolio. Ameritas Prtnrs stated it has 3,346 shares. Connor Clark & Lunn Management has 0% invested in Fate Therapeutics, Inc. (NASDAQ:FATE). Vigilant Cap Management Ltd Liability Com has 1,000 shares. Moreover, Ecor1 Cap Limited Company has 1.19% invested in Fate Therapeutics, Inc. (NASDAQ:FATE) for 2.26 million shares. 256,000 are owned by Bridgeway Inc. 2.47 million were reported by Polaris Venture Management V Limited Liability Corporation. Rhumbline Advisers reported 41,527 shares.

Since October 13, 2017, it had 0 buys, and 3 insider sales for $148,927 activity. Another trade for 17,168 shares valued at $66,600 was sold by Wolchko J Scott. 13,225 Fate Therapeutics, Inc. (NASDAQ:FATE) shares with value of $51,203 were sold by Shoemaker Daniel D.

Analysts expect Fate Therapeutics, Inc. (NASDAQ:FATE) to report $-0.26 EPS on March, 15.They anticipate $0.05 EPS change or 23.81 % from last quarter’s $-0.21 EPS. After having $-0.26 EPS previously, Fate Therapeutics, Inc.’s analysts see 0.00 % EPS growth. The stock increased 1.16% or $0.09 during the last trading session, reaching $8.08. About 145,524 shares traded. Fate Therapeutics, Inc. (NASDAQ:FATE) has risen 166.12% since February 15, 2017 and is uptrending. It has outperformed by 149.42% the S&P500.

Fate Therapeutics, Inc. (NASDAQ:FATE) Ratings Coverage

Among 9 analysts covering Fate Therapeutics (NASDAQ:FATE), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Fate Therapeutics had 12 analyst reports since October 6, 2015 according to SRatingsIntel. The stock of Fate Therapeutics, Inc. (NASDAQ:FATE) has “Outperform” rating given on Tuesday, November 8 by Wedbush. The company was initiated on Tuesday, April 12 by BMO Capital Markets. Leerink Swann initiated the stock with “Buy” rating in Friday, September 8 report. BMO Capital Markets maintained it with “Buy” rating and $7.0 target in Wednesday, November 1 report. The stock of Fate Therapeutics, Inc. (NASDAQ:FATE) has “Outperform” rating given on Tuesday, October 6 by Raymond James. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, December 13. As per Thursday, September 22, the company rating was initiated by Roth Capital. TH Capital initiated the stock with “Buy” rating in Thursday, September 22 report. As per Thursday, October 12, the company rating was reinitiated by H.C. Wainwright. Wells Fargo initiated the shares of FATE in report on Friday, December 4 with “Outperform” rating.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company has market cap of $412.06 million. The Company’s immuno-oncology product candidates include FATE-NK100, a natural killer cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors. It currently has negative earnings. The company's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorders.

Another recent and important Fate Therapeutics, Inc. (NASDAQ:FATE) news was published by Fool.com which published an article titled: “Here’s Why Fate Therapeutics Rose as Much as 18% Today” on January 23, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: